[go: up one dir, main page]

WO2007081975A3 - Méthode de traitement de la sclérose en plaques - Google Patents

Méthode de traitement de la sclérose en plaques Download PDF

Info

Publication number
WO2007081975A3
WO2007081975A3 PCT/US2007/000575 US2007000575W WO2007081975A3 WO 2007081975 A3 WO2007081975 A3 WO 2007081975A3 US 2007000575 W US2007000575 W US 2007000575W WO 2007081975 A3 WO2007081975 A3 WO 2007081975A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
patient
treating multiple
symptom
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/000575
Other languages
English (en)
Other versions
WO2007081975A2 (fr
Inventor
Irit Pinchasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Publication of WO2007081975A2 publication Critical patent/WO2007081975A2/fr
Publication of WO2007081975A3 publication Critical patent/WO2007081975A3/fr
Priority to IL192555A priority Critical patent/IL192555A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode permettant de soulager un symptôme d'un patient souffrant d'une forme de rechute de la sclérose en plaques et consistant à administrer de manière préiodique au patient, par injection sous-cutanée, une dose unique d'une composition pharmaceutique renfermant 40 mg d'acétate de glatiramère, de manière à soulager ainsi le symptôme du patient. L'invention concerne également une méthode permettant de réduire des lésions rehaussées par le Gd dans le cerveau et une composition pharmaceutique en dosage unitaire.
PCT/US2007/000575 2006-01-11 2007-01-09 Méthode de traitement de la sclérose en plaques Ceased WO2007081975A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL192555A IL192555A0 (en) 2006-01-11 2008-07-01 Method of treating multiple sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75858006P 2006-01-11 2006-01-11
US60/758,580 2006-01-11

Publications (2)

Publication Number Publication Date
WO2007081975A2 WO2007081975A2 (fr) 2007-07-19
WO2007081975A3 true WO2007081975A3 (fr) 2007-12-21

Family

ID=38257005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/000575 Ceased WO2007081975A2 (fr) 2006-01-11 2007-01-09 Méthode de traitement de la sclérose en plaques

Country Status (3)

Country Link
US (1) US20070161566A1 (fr)
IL (1) IL192555A0 (fr)
WO (1) WO2007081975A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9155776B2 (en) 2009-08-20 2015-10-13 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
US9499868B2 (en) 2011-10-10 2016-11-22 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
ES2572811T3 (es) * 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
MX2007009296A (es) * 2005-02-02 2007-09-21 Teva Pharma Proceso para producir mezclas de polipeptidos usando hidrogenolisis.
KR20100102620A (ko) * 2007-11-28 2010-09-24 테바 파마슈티컬 인더스트리즈 리미티드 임상적 확진 다발성 경화증의 발병 지연 방법
EP2277050B2 (fr) 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analyse de compositions copolymères d'acides aminés
EP2307456B1 (fr) 2008-06-27 2014-10-15 Amgen Inc. Inhibition de l ang-2 pour traiter la sclérose en plaques
PL2275086T3 (pl) * 2009-07-15 2012-09-28 Teva Pharma Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania
AU2013203367C1 (en) * 2009-08-20 2018-01-18 Yeda Research & Development Co., Ltd Low frequency glatiramer acetate therapy
AU2013201328B2 (en) * 2009-08-20 2016-05-26 Yeda Research & Development Co. Ltd. Low frequency glatiramer acetate therapy
AU2015101564B4 (en) * 2009-08-20 2016-06-09 Yeda Research & Development Co., Ltd Low frequency glatiramer acetate therapy
EP2470269A1 (fr) * 2009-10-22 2012-07-04 Sanofi-Aventis U.S. LLC Utilisation de l'association du tériflunomide et de l'acétate de glatiramère pour traiter la sclérose en plaques
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
PT2627669T (pt) 2010-10-11 2016-11-24 Teva Pharma Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero
WO2013009885A2 (fr) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation de diéthylamide de copolymère
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CA2884267A1 (fr) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Marqueurs biologiques predictifs de la reponse clinique a l'acetate de glatiramer
WO2014128079A1 (fr) * 2013-02-19 2014-08-28 Synthon B.V. Formulation multidose d'acétate de glatiramère
EP2968559A4 (fr) * 2013-03-12 2016-11-02 Teva Pharma Thérapie d'induction par rituximab suivie d'une thérapie par acétate de glatiramère
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
EP3506921B1 (fr) 2016-08-31 2023-05-17 Mapi Pharma Ltd Systèmes de libération retardée comprenant de l'acétate de glatiramère
CA3050086A1 (fr) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Systemes de depot de glatiramere pour le traitement de formes progressives de sclerose en plaques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091573A1 (fr) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Traitement combine a base d'acetate de glatiramer et d'alphacalcidol, destine au traitement de la sclerose en plaques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
WO2002076503A1 (fr) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091573A1 (fr) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Traitement combine a base d'acetate de glatiramer et d'alphacalcidol, destine au traitement de la sclerose en plaques

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US9155776B2 (en) 2009-08-20 2015-10-13 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
US9402874B2 (en) 2009-08-20 2016-08-02 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
US9499868B2 (en) 2011-10-10 2016-11-22 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product

Also Published As

Publication number Publication date
WO2007081975A2 (fr) 2007-07-19
US20070161566A1 (en) 2007-07-12
IL192555A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
WO2007081975A3 (fr) Méthode de traitement de la sclérose en plaques
WO2004103297A3 (fr) Polytherapie a base d'acetate de glatiramer et de mitoxantrone destinee au traitement de la sclerose en plaques
WO2009034134A3 (fr) Utilisation de peptides natriurétiques pour le traitement des syndromes de l'œdème de quincke
WO2008022256A3 (fr) Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
WO2008069941A3 (fr) Forme pharmaceutique d'ibuprofène à libération modifiée
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
RU2015127794A (ru) Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
WO2006029036A3 (fr) Therapie combinee avec du glatiramere acetate et de la n-acetylcysteine pour traiter la sclerose en plaques
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
JP2012501973A5 (fr)
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
WO2007012019A3 (fr) Medicaments contenant famotidine et ibuprofene, et administration desdits medicaments
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
EP1849462A3 (fr) Procédé d'atténuation des signes et des symptômes de la spasticité
WO2008030830A3 (fr) Composition à libération prolongée et son procédé d'utilisation
WO2007138466A3 (fr) Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
WO2005058233A3 (fr) Methodes de traitement d'une pancreatite aigue
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
WO2005081742A3 (fr) Formulations de dosages oraux de testostérone et procédés associés
WO2008012796A3 (fr) Compositions pharmaceutiques comprenant ccl2 et leur utilisation dans le traitement d'une inflammation
WO2008066626A3 (fr) Procédés pour le traitement de troubles en rapport avec aβ, et compositions pour ceux-ci
WO2009019708A3 (fr) Compositions pharmaceutiques et procédés pour le traitement du cancer
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
WO2012042197A3 (fr) Composition pharmaceutique faiblement dosée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 192555

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07717784

Country of ref document: EP

Kind code of ref document: A2